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Summary points
• Pregnant women, children < 15 years old and, HIV-infected persons contribute
approximately 20% of the global tuberculosis (TB) burden, with an estimated 216,000,
1,000,000, and 1,040,000 cases each year, respectively, yet these populations are cur-
rently largely excluded from TB clinical trials, leading to suboptimal treatment and poor
access to new therapeutics.
• Special considerations in these populations include specific TB disease spectrum and
severity, lower sensitivity of commonly used TB diagnostic tests, potential differential
drug dosing and treatment responses, drug–drug interactions, and challenges in acquir-
ing high-quality data through clinical trials.
• To counter the automatic exclusion of pregnant and lactating women that currently per-
vades the TB trial landscape, early discussions among trialists, pharmaceutical compa-
nies, maternal–child clinical experts, ethicists, and regulatory bodies are needed to
address risks, benefits, and compelling rationale for inclusion. Reconsenting women
when pregnancy occurs on a trial to allow continuation of study drug by informed
choice is a practical and valuable approach to expand the currently limited evidence
base.
• Children tend to have less severe, often paucibacillary TB disease and may respond bet-
ter to treatment than adults. Consequently, trials of shorter, less intense TB treatment
regimens in children are needed; pharmacokinetic and safety studies should be initiated
earlier and involve age groups in parallel rather than in an age-de-escalation approach.
More rapid development of child-friendly drug formulations is needed.
• All HIV-infected populations, including those with advanced disease, who are likely to
be the intended population of the TB therapy, should be involved in Phase IIb and/or
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Introduction
Globally, 10 million cases of active tuberculosis (TB) disease and 1.6 million TB-related deaths
occurred in 2017 [1]. Pregnant and postpartum women, children < 15 years old, and HIV-
infected persons account for 20% of the global TB burden, with an estimated 216,000,
1,000,000, and 1,040,000 cases each year, respectively [1,2]. Special considerations in these
populations include TB disease spectrum and severity, lower diagnostic sensitivity, possible
differential treatment responses, drug dosing and interactions, and challenges in acquiring
high-quality data through clinical trials [3–5]. Without clear consideration of actual risks and
benefits of trial participation, pregnant women have been uniformly excluded from TB thera-
peutic trials, especially for multidrug-resistant (MDR) TB [6,7], based on fears of harming the
fetus and legal liability [8]. Children have better treatment outcomes than adults for most
forms of TB, but they present different pharmacologic responses to drugs and typically require
higher mg/kg doses, especially if very young [9–11]. HIV-infected persons experience compli-
cated drug–drug interactions (DDIs) and worse TB treatment outcomes than HIV-uninfected
persons and have 2–3 times greater likelihood of TB-related mortality [12]. In March 2018, the
World Health Organization (WHO) held a technical consultation focused on advancing clini-
cal trial design for more successful development of new TB treatments [13], including enroll-
ment of key populations that may be currently underrepresented in clinical trials. Although
many such populations exist, including migrants, prisoners, homeless people, and healthcare
workers, the technical consultation discussions were concentrated on three populations and
were framed around five questions (Box 1). This review is part of a Collection, “Advances in
Clinical Trial Design for the Development of New TB Treatments: A Call for Innovation,” and
highlights key aspects, barriers, and potential solutions to conducting TB therapeutic clinical
trials in pregnant and lactating women, children, and HIV-infected persons [14].
Box 1. Five questions addressed during discussions about key
populations in clinical trials of TB therapeutics [13]
1. Aside from the use of well-designed trials based on solid preclinical data con-
ducted under the protections outlined in existing regulations, what are the biggest
barriers to including key populations in clinical trials? What approaches or mea-
sures might stimulate greater inclusion of key populations in trials, including
greater community engagement and awareness?
2. What would make the inclusion of key populations easier for researchers?
3. What special considerations need to be taken into account to include key popula-
tions into trials? Can they be included as an additional arm of study? A part of a
larger patient group?
4. At what phase is it most appropriate to include key populations?
5. Areas where key populations are included should be prioritized based on burden.
What are these priority areas, and what are the requirements for each population?
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Why is it important to include key populations in clinical trials?
After unanticipated harm occurred from in utero exposure to thalidomide and diethylstilbes-
trol in the 1960s and 1970s, the United States Food and Drug Administration (FDA) enacted
policies to protect women research participants of reproductive age from teratogenic exposure
[15]. An unintended consequence has been the uniform exclusion of pregnant women from
Phase III trials of TB therapies, even for MDR and extremely drug-resistant (XDR) TB [7,8].
Exclusion has been based on concerns of legal liability as well as new or increased frequency/
severity of adverse events and potential unpredictability of such events in pregnancy or the
postpartum period. Ethical complexities and insufficient market interests for developing pedi-
atric formulations and concerns of potential DDIs among antiretrovirals and TB therapies are
among the factors preventing adequate trial data from being collected from child and HIV–
TB-coinfected populations, particularly those with advanced immunosuppression.
Although concerns of potential harm from TB therapeutics are understandable, a scientific
and ethical foundation exists for including pregnant and lactating women and other key popu-
lations in trials of TB medicines for prevention and treatment [16,17]—namely, the need for
effective treatment and evidence-based answers to enable patients to make fully informed
choices for themselves (and the developing fetus) based on risks and benefits of specific thera-
pies. However, these data are rarely available [8,16–20]. Pregnant and lactating women, chil-
dren, and HIV-infected persons each have unique features. Thus, assumptions made from
therapeutic TB trials excluding these populations are not always applicable, and data cannot be
reliably extrapolated from other populations. Without high-quality data from targeted studies,
many unanswered questions remain concerning optimal TB regimens, optimal dosing of new/
existing TB drugs, and their safety.
Although the landmark zidovudine trial paved the way for rigorous study of HIV antiretro-
virals in pregnancy [21], this has yet to translate to the TB arena. TB treatment in pregnancy
and lactation is mostly based on case reports and small case series [6,7,22]. As a result, medica-
tions, including those for TB, are often prescribed in pregnancy without the knowledge
required to achieve appropriate doses for optimal therapeutic effect [23,24], and WHO and
Centers for Disease Control and Prevention (CDC) recommend conflicting treatment guide-
lines for drug-susceptible TB (i.e., 6-month regimen, including pyrazinamide versus 9-month
regimen, excluding pyrazinamide, respectively) [25,26]. Overall, uncertainty persists concern-
ing optimal drug selection, safety, and timing of TB treatment initiation and whether safety
signals differ by trimester.
In pediatrics, off-label drug use is a common practice and is largely based on adult studies
without rigorously conducted pharmacokinetics (PK), dose-finding, or formulation studies in
children [27]. Children, however, are not small adults. The age-related risk of progressing to dis-
ease after TB infection and excess risk of disseminated forms of TB in children mandate the
study of new therapies in this group. Additionally, it is critical to include young, small children
in trials given that the effects of age and weight on PK are most pronounced and challenging to
predict in this subgroup. Notably, the 2011 revised WHO dosing guidelines for first-line TB
drugs in children< 12 years old were based on studies suggesting that young children require
higher mg/kg doses [28]. However, the evidence supporting these dosing recommendations was
limited and especially lacking in studies using high-quality drug formulations. With a wide spec-
trum of disease, children with paucibacillary intrathoracic TB may in fact require lower total
drug exposures (lower dose and/or shorter regimen), whereas children with more severe pulmo-
nary TB or disseminated disease (e.g., TB meningitis) may require higher doses than adults.
Regardless of age, HIV-infected persons are at highest risk of developing TB and have a
high TB-related mortality. In this population, differential responses to TB treatment and
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preventive regimens and overlapping toxicities between HIV therapies and TB therapies are
such that safety, toxicity, and DDIs cannot be predicted by modeling alone. In particular,
adults and children with advanced HIV disease have more complex and unknown responses,
toxicities, and DDIs than HIV-infected persons with higher CD4 T-cell counts. This subgroup
is important to include in TB trials, as they may benefit from new TB therapies, but this needs
to be ascertained carefully and is best done in a clinical trial setting.
Clearly, gathering evidence under rigorous scientific conditions is among the most compel-
ling reasons for inclusion of key populations in TB drug research [16,17,23,29,30], especially
because safety signals can be more readily interpreted in a clinical study setting. Controlled tri-
als are also essential to assess specific TB treatment–associated outcomes and adverse effects.
However, there are also issues of justice and access to the benefits of research participation.
Inclusion in clinical trials is likely the only way for pregnant/lactating women, children, ado-
lescents, and HIV-infected persons to access or accelerate access to new regimens and
medications.
Overview of trial design considerations for key populations
Pregnant and lactating women
Overview of TB in pregnant and lactating women. In most countries, TB incidence
peaks in women of reproductive age, irrespective of HIV [22]. Pregnancy is not routinely
included in national/international TB registries, but worldwide, at least 216,000 TB cases are
reported to occur in pregnancy annually [2]. Immune changes in pregnancy may alter the risk
of disease, TB presentation, and diagnosis [4,31,32]. Complications of TB developing during
pregnancy and lactation are well known and can include maternal death, preeclampsia, vaginal
bleeding, and maternal death as well as prematurity, low birth weight, and fetal or infant
death, particularly if TB is inadequately treated [22,33,34]. Notably, many TB drugs are catego-
rized by the US FDA as former category C (Table 1), and many have undetermined placenta
crossing, fetal, or lactation compatibility [6] (Table 1). In addition, drug absorption, distribu-
tion, metabolism, and elimination may be modified in pregnancy and lactation [35,36], and
increased clearance of some drugs requires dose modification, particularly in the third trimes-
ter [37]. Lastly, there is often a significant time gap between licensure of medicines and preg-
nancy-specific data being obtained. HIV antiretrovirals, which have more data in pregnancy,
still had a median gap of 6 years from licensure to access [38].
TB trial design considerations and recommendations for pregnant and lactating
women. In 2018, the US FDA and the US Federal Task Force on Research Specific to Preg-
nant Women and Lactating Women (PREGLAC) issued separate documents to accelerate
inclusion of pregnant and lactating women in clinical trials. The FDA draft guidance [23] out-
lines prerequisites for “reasonable” and “ethically justifiable” inclusion of pregnant women in
premarketing studies (i.e., “adequate” preclinical data plus the potential to provide unique
clinical benefit to the woman or fetus) and postmarketing studies (i.e., “adequate” nonclinical
data plus established safety in nonpregnant women and no alternate means to extrapolate effi-
cacy and/or assess safety). Generally, Phase I and II trials should be conducted in nonpregnant
women of reproductive age, and inclusion of pregnant women should be considered in Phase
III or IV trials based on clear risks and benefits assessment. Critical trial components include
PK data with minimum requirements (i.e., gestational age at enrollment, gestational timing/
duration of drug exposure, and pregnancy outcomes [adverse maternal, fetal, and neonatal
events]), obstetrical care meeting recognized standards for pregnant women on trial, and fol-
low-up safety data among infants of mothers with investigational drug exposure. The FDA
also provides guidance regarding evaluation of systemic drug exposure to fetus/newborn,
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Table 1. FDA/WHO pregnancy classification and select maternal–fetal and reproductive toxicity characteristics of drugs used to treat TB.














Isoniazid C 1 Y CNS defects Yes (<5%) No Possible increased hepatotoxicity




Yes Possible postpartum hemorrhage;
interacts with NNRTIs, PIs,
decreases efficacy of hormonal
contraceptives
Ethambutol C 1/C Yes Jaundice UD (minimal
passage, <5%)
Yes (low incidence) –
Pyrazinamide C 1/C Unknown Jaundice UD (excreted in
breast milk)
UD Differential recommendation
between US CDC and WHO for
use in TB treatment in pregnancy
Rifabutin B – UD – UD No Possible postpartum hemorrhage;
interacts with NNRTIs, PIs,
decreases efficacy of hormonal
contraceptives
Rifapentine C – UD – UD Yes Possible postpartum hemorrhage;
interacts with NNRTIs, PIs,
decreases efficacy of hormonal
contraceptives
Aminoglycosides
Capreomycin C Not A–C Yes – UD Yes –





Kanamycin D Not A–C Yes Ototoxicity Yes (minimal
passage)
No –
Amikacin D C Yes Ototoxicity UD UD –
Levofloxacin C A Yes Possible bone Yes No –
Moxifloxacin C A Yes Possible bone UD No –
Gatifloxacin C Not A–C UD Possible bone UD No –
Ethionamide/
prothionamide
C C UD Developmental
anomalies




C C UD Diarrhea No No –
Cycloserine C B UD – Yes UD Congenital sideroblastic anemia
Terizidone – B UD – Yes UD –
Thioacetazone – Not A–C UD – UD UD –
Clofazimine C B UD Reversible skin
pigmentation
UD No –
Clarithromycin C Not A–C Yes (0.15) – UD No –
Amoxicillin-
clavulanic acid








C C UD – UD No –
High-dose
isoniazid
C Not A–C Yes (0.73) CNS defects UD No Possible hepatotoxicity
Bedaquiline B A UD – UD No Drug accumulation in tissues
Delamanid Not
approvedc
C UD – UD Yes Embryofetal toxicity at
maternally toxic doses in rabbits;
breast milk concentration 4×
higher than blood in rats
(Continued)
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women who become pregnant on study, obtaining adequate nonclinical reproductive and
developmental toxicology data, identifying trial populations standing to benefit most while
minimizing risk, gestational timing of investigational drug exposure relative to fetal develop-
ment, and appropriate control populations. In its report, PREGLAC highlighted 15 recom-
mendations to encourage research on therapies during pregnancy and lactation, the majority
of these being of particular relevance to TB therapeutics [18].
An international group of experts has also issued recommendations with particular refer-
ence to TB treatment trials: pregnant and lactating women should be eligible for Phase III
MDR TB trials unless a compelling reason for exclusion exists, drug companies should be
encouraged to complete reproductive toxicity studies of TB drugs before beginning Phase III
studies, trials of shortened treatment regimens for latent TB infection (LTBI) should be
designed to improve completion rates and reduce risk of progression in pregnancy and lacta-
tion, targeted PK studies should be nested in all TB studies when evidence is lacking, and a TB
pregnancy registry should be established to accumulate data on maternal–infant outcomes [6].
These were discussed at the March 2018 WHO technical consultation discussions, and the fol-
lowing propositions were made.
Trial designs for active TB disease in pregnant and lactating women. Inclusion in
Phase III trials is likely the only way to access more optimal regimens/newer agents and gener-
ally the only way to obtain safety, PK, and outcome data in this population, as postmarketing
studies are not prioritized for funding or by regulatory bodies. In this respect, because MDR
TB has significant morbidity and mortality and because many MDR TB drugs are associated
Table 1. (Continued)
















– UD – UD UD
Sutezolid Not
approved
– UD – UD UD
Table adapted from [6].
a The former FDA categories were defined as follows: category A: adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester
of pregnancy (and there is no evidence of risk in later trimesters); category B: animal reproduction studies have failed to demonstrate a risk to the fetus, and there are no
adequate and well-controlled studies in pregnant women; category C: animal reproduction studies have shown an adverse effect on the fetus, and there are no adequate
and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks; category D: there is positive
evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use
of the drug in pregnant women despite potential risks; category X: studies in animals or humans have demonstrated fetal abnormalities, and/or there is positive evidence
of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly
outweigh potential benefits. The US FDA now uses narrative summaries to communicate what information is known and not known for individual drugs. However, the
former risk categorization is still felt to be useful and has been used in this table. https://www.fda.gov/about-fda/economic-impact-analyses-fda-regulations/summary-
content-and-format-labeling-human-prescription-drug-and-biological-products-requirements.
Additional information about each drug can be found at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm.
b Information on breast milk transfer of TB drugs is collated on LactMed, the National Library of Medicine searchable database of drugs to which breastfeeding mothers
may be exposed. https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm.
c Approved by European Medicine Association and other non-FDA agencies outside the US.
Abbreviations: CDC, Centers for Disease Control and Prevention; CNS, central nervous system; FDA, Food and Drug Administration; NNRTI, nonnucleoside reverse
transcriptase inhibitor; PI, protease inhibitor; PK, pharmacokinetics; UD, undetermined; WHO, World Health Organization
https://doi.org/10.1371/journal.pmed.1002882.t001
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with substantial intolerance and adverse effects, it is reasonable to consider inclusion of preg-
nant and lactating women in Phase III MDR TB treatment trials when there is no teratogenic-
ity signal from reproductive toxicity. However, to our knowledge, no Phase III trial of MDR
TB treatment has included pregnant women to date. To counter the automatic exclusion of
pregnant women that currently pervades the TB trial landscape, early discussion among trial-
ists, pharmaceutical companies, maternal–child experts, ethicists, and regulatory bodies are
needed to address risks, benefits, and compelling rationale for inclusion [7].
Another important approach is to capture pregnancy outcomes among women who
become pregnant while participating in a therapeutic trial. Current practice is to discontinue
study drugs at the time pregnancy is identified and define the participant as “unassessable.”
Instead, newly pregnant participants should be reconsented, offering the option to continue
the study drug unless teratogenicity is known or suspected. All current information concern-
ing the drug/regimen during pregnancy should be reviewed and communicated, including
any shifts in risk–benefit balance, and carefully described to the patient. Examples of such sec-
ondary consent forms have been developed and are already used in some clinical trials [4].
Furthermore, support and mandates to standardize systematic data collection and reporting to
a global pregnancy TB treatment registry is urgently needed. Similar to the HIV antiretroviral
therapy (ART) registry, data from pregnancy, delivery, and infancy until age 6 months should
be mandated [39, 40]. Whether from trials or registries, collecting PK and outcome data
among pregnant women will be invaluable and can be pooled for analysis once sufficient data
have accumulated. Novel physiologically based PK and pharmacodynamics (PD) modeling
can also be applied to estimate drug dosing in pregnancy, but prediction of safety and toxicity
profiles still requires trial data [41].
The postmarketing opportunistic PK model illustrated by International Maternal Pediatric
Adolescent AIDS Clinical Trials Network (IMPAACT) P1026s [42] is another approach to
advance the evidence base (Table 2). This protocol is enrolling pregnant and lactating women
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to assess the safety and PK of first- and second-line TB drugs routinely used in clinical practice
as regimens evolve [43]. Assessments are made by pregnancy trimester, at delivery, and post-
partum, with careful monitoring/ascertainment of maternal, fetal, and infant outcomes. PK of
multiple TB drugs are captured in maternal plasma by pregnancy stage and from cord blood,
breast milk, and infant samples along with relevant maternal–fetal–infant safety and clinical
outcomes. This model also allows for study of DDIs between TB drugs and both antiretrovirals
and postpartum contraceptives [44,45].
Trial designs for TB preventive therapy in pregnant and lactating women. Despite the
large burden of LTBI and risk of progression to active TB, pregnant women have been system-
atically excluded from the>12 Phase III and postmarketing clinical studies of TB preventive
therapy [6,46]. Data from nonpregnant individuals and small observational studies have
informed the guidance for isoniazid preventive therapy (IPT) in pregnancy [47,48]. The first
randomized placebo-controlled trial to assess safety and optimal timing of IPT in HIV-infected
pregnant women in high-TB-burden settings (IMPAACT P1078) was recently completed
(Table 2) [49]. The relative risks and benefits of immediate antepartum versus deferred post-
partum IPT initiation was assessed and included careful monthly monitoring of maternal,
fetal, pregnancy, and infant outcomes. No differences in maternal safety outcomes, maternal–
infant TB, or infant safety outcomes were found between arms, but an increase in composite
adverse pregnancy outcomes was observed in the immediate IPT arm. Shorter-course, effica-
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IMPAACT trial protocols can be found at https://impaactnetwork.org/studies/index.asp; NCT is the https://clinicaltrials.gov/ identification number; trials including
HIV-infected (HIV+) are demarcated using bolded “HIV+” in the Study Population column.
Abbreviations: 1HP, 1 month of daily H and P; 3HP, 3 months of weekly H and P; ACTG, AIDS Clinical Trials Group; ARV, antiretroviral; BDQ, bedaquiline; CROI,
Conference on Retroviruses and Opportunistic Infections; De, delaminid; DS, drug-sensitive; DR, drug-resistant; EDCTP, European & Developing Countries Clinical
Trials Partnership; GA, gestational age; H, isoniazid; HIV, human immunodeficiency virus; IMPAACT, International Maternal Pediatric Adolescent AIDS Clinical
Trials Network; IPT, isoniazid preventive therapy; LTBI, latent TB infection; MDR, multidrug-resistant; MRC, Medical Research Council; NIH, National Institutes of
Health; NIAID, National Institute of Allergy and Infectious Diseases; NICHD, Eunice Kennedy Shriver National Institute of Child Health and Human Development; P,
rifapentine; PD, pharmacodynamics; PK, pharmacokinetics; TB, tuberculosis; TBD, to be determined
https://doi.org/10.1371/journal.pmed.1002882.t002
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greater advocacy and effort on behalf of groups focused on high-quality data for pregnant
women, postmarketing trials assessing shorter LTBI regimens are also now underway or in
development for pregnant women (Table 2). These include IMPAACT P2001 (PK and safety
of 3 months of weekly isoniazid and rifapentine [3HP]) and IMPAACT Concept 5021 (safety,
tolerability, optimal timing, and PK of 3HP versus 1 month of daily isoniazid and rifapentine
[1HP]).
The IMPAACT network serves as an excellent example of how a group focused on thera-
peutics in pregnant women can make major strides to close the evidence gap (Table 2). Estab-
lishing a global TB registry and inclusion of pregnant women into relevant Phase III TB trials
should be the next step. TB therapeutic protocols under development should be reviewed by
experts in the care of TB in pregnant women, maternal–fetal medicine specialists, regulatory
authorities, and bioethicists who can further comment on the risks and benefits of including
pregnant women during the trial planning stage.
Children
Overview of TB in children. Globally, approximately 10% of TB cases occur among chil-
dren (0–14 years) annually. Of the estimated 1,000,000 cases in 2017, only 360,000 were noti-
fied to WHO, yet children < 5 years old are particularly vulnerable, accounting for>50% of
child TB cases and approximately 80% of child TB-related deaths [1]. In contrast to the situa-
tion in adults, children display a wide spectrum of TB disease phenotypes ranging from nonse-
vere, often paucibacillary pulmonary/intrathoracic TB (usually uncomplicated lymph node
disease) to severe disseminated TB and TB meningitis, a major cause of TB-related morbidity
and mortality in children [52]. Paucibacillary intrathoracic TB (minimal or nonsevere TB) is
more prevalent overall, and TB treatment outcomes are generally good for drug-sensitive (DS)
and drug-resistant (DR) TB (provided treatment is initiated early), even when considerably
lower doses of antituberculosis drugs were used for DS TB [53]. However, risk of progression
from infection to active TB disease varies substantially by age and with HIV infection. PK also
varies because of effects related to child age and size. Young children, particularly <2 years
old, are at much higher risk of developing TB and severe disease forms [54] and typically
require higher mg/kg doses of most TB drugs to reach adult therapeutic targets. Finally, TB
diagnosis and treatment response monitoring rely on clinical, more subjective measures in at
least 60% of children, as young children cannot spontaneously produce sputum for examina-
tion, and paucibacillary disease (sputum smear negative) is diagnosed by culture, the current
diagnostic gold standard, in only 30%–40% of cases [55].
TB trial design considerations and recommendations for children. With concerted
effort and advocacy along with academic and government funding and recognition from regu-
latory agencies, the pediatric TB trial landscape has substantially improved, as evidenced by
the number of ongoing and planned studies of treatment for the diverse forms of TB in chil-
dren (Table 3). The ways in which pediatric and adult TB differ inform the type of pediatric
TB drug trials needed and their key design considerations. If children are to be included in
adult trials, different inclusion and exclusion criteria may be needed, and definitions used to
determine study endpoints (e.g., unfavorable outcome) require careful consideration because
of differing clinical features and diagnostic challenges of TB in children compared with adults.
Diagnosis, treatment response monitoring, and characterization of treatment outcome in chil-
dren often depend on clinical measures that are relatively imprecise compared with the diag-
nostic standard used in adults. Limited availability of pediatric-friendly formulations also
poses a barrier to enrollment of younger children. Large Phase III clinical trials may not be fea-
sible or always needed for children, yet timely PK and safety data in children, especially in
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Abbreviations: 1HP, 1 month of daily isoniazid and rifapentine; 3HP, 3 months of weekly isoniazid and rifapentine; AECID, Agencia Española de Cooperación
Internacional para el Desarrollo (Spanish Agency for International Development Corporation); ART, antiretroviral therapy; ARV, antiretroviral; AFD, French
Development Agency; ATT, antituberculosis therapy; BDQ, bedaquiline; CDC, Centers for Disease Control and Prevention; De, delamanid; DFID, British Department
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Consortium; TST+, tuberculin skin test positive; WHO, World Health Organization; XDR, extremely drug-resistant; Z, pyrazinamide
https://doi.org/10.1371/journal.pmed.1002882.t003
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young and HIV-infected children, is critical to inform policy guidance on new therapies
deemed to be safe and efficacious in adolescent and adult populations. Modified study designs
should be explored to accelerate implementation of PK and safety studies in children while
ensuring the validity of the trial results and the safety of all child participants. Unlike younger
children, adolescents (typically�10 years old) have TB disease characteristics similar to adults,
including frequent cavitating disease. Adolescents should therefore be routinely considered for
inclusion in adult Phase IIb and III trials. However, similar to pregnant and lactating women,
legal requirements for child participation in clinical trials are often barriers (perceived or real)
and vary by country. When feasible and justified through appropriate consultation, the inclu-
sion of children should be carefully considered and supported early during protocol develop-
ment. Summaries of considerations for the types of trials needed for children, including
practical and ethical considerations regarding inclusion of children in TB trials, can be found
elsewhere [5, 56]. Highlights and considerations discussed at the WHO technical consultation
are discussed below based on updated information.
Trial designs for active TB disease in children. Considering scenarios in which disease
progression and/or response to an intervention are expected to differ among adults and chil-
dren, the classical approach is to conduct PK studies in children to establish appropriate dos-
ing followed by safety and efficacy trials. For example, because children often develop less
severe, paucibacillary TB, it is plausible that children would respond equally well (i.e., treat-
ment would have at least equal efficacy) to shorter, less intense, and less complex regimens
than adults while potentially improving their tolerability, safety, acceptability, and adherence.
Identifying such regimens would require an efficacy study in children, as regimens that
could be effective in children may be rejected in adult trials. Based on these assumptions,
the currently ongoing Shorter Treatment for Minimal TB in Children (SHINE) trial
(ISRCTN63579542) investigates whether a shorter 4-month regimen can be used for children
with less severe disease than the standard 6-month adult regimen (Table 3). Other examples
include the treatment of LTBI (discussed below) and TB meningitis. TBM Kids (NCT
02958709) is the only currently open trial to assess the treatment of TB meningitis, which espe-
cially affects very young children.
In contrast, when considering scenarios in which children and adults are expected to have
similar disease progression, response to an intervention, and exposure response, then it is logi-
cal to conduct PK studies to achieve drug exposures similar to adults, followed by safety trials
at the proper dose. For individual TB medications, it is reasonable to assume that the response
in children would be at least as good as in adults. Therefore, repeating formal efficacy studies
for individual TB drugs in children is unnecessary. Instead, the focus should be on trials to
establish PK, dose, and safety in children. Many of the trials shown in Table 3 are such studies,
including the pediatric trials of the recently approved drugs bedaquiline and delamanid.
Another example is the Opti-Rif Kids trial (South African trial identifier 27-0117-5411), which
aims to characterize rifampin doses among children 0 to<12 years old that approximate expo-
sures observed in adults receiving higher rifampin doses (�35 mg/kg) in adult trials [57]. Both
age and weight have an impact on PK in children and must be considered in the design of
pediatric PK studies of TB drugs. It is especially critical to include young, small children given
that the effects of age and weight are most pronounced in this subgroup. Traditionally, age-de-
escalation studies have been a major feature of pediatric PK-focused Phase I/II trials whereby
children have been studied in series, rather than in parallel, starting with older children and
progressing to younger children. This approach, however, should be avoided if possible: it is
costly and time consuming; older children may have limited ability to inform dosing and safety
in the youngest children, for whom there is the most uncertainty; and regulatory agencies do
not strictly require age de-escalation [5]. HIV infection and malnutrition are additional,
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important covariates to consider when designing pediatric trials, and these children should be
included in TB therapeutic trials.
If the exposure response to an intervention is expected to differ among children and adults,
then PK/PD should be conducted to establish the exposure response in children followed by
safety studies. If a PD marker is unavailable to assess pharmacologic response, as is typically
the case in bacteriologically unconfirmed TB (i.e., clinically diagnosed TB), then PK studies
should be followed by safety and efficacy studies [56]. The traditional assumption that expo-
sure response is similar among children and adults for all types of TB is being questioned. For
example, most children with pulmonary TB are sputum smear and culture negative and there-
fore have different bacillary burden compared with adults with cavitating disease. Given that
childhood TB may differ in disease type and severity compared with adult TB, target concen-
trations for treatment of many forms of childhood TB may differ from those in adults. This
provides additional justification for efficacy trials in children in some instances. For example,
there are no data from trials investigating regimens to prevent MDR TB in either adult or
child household contacts. TB-CHAMP (ISRCTN92634082) is a Phase III cluster-randomized
placebo-controlled study that is specifically powered to evaluate the efficacy of 6 months of
levofloxacin versus placebo for the prevention of TB in young child household contacts
(age < 5 years) of MDR TB cases. Although not powered for efficacy in children, the PHOE-
NIx trial (A5300/I2003) plans to study adult, HIV-infected, and child contacts of MDR TB
using delamanid versus isoniazid and is a good example of how key populations can be studied
within a single Phase III efficacy trial (Table 2).
Lastly, child-friendly formulations are important to ensure accurate, acceptable, and palat-
able doses in young children. The development and implementation of bioequivalence studies
of pediatric formulations is lengthy and should start much earlier during the drug develop-
ment process. A potential temporary solution is to better understand how manipulating the
adult formulation affects the PK to inform pediatric use. The TASK-002 study successfully
assessed the relative bioavailability of 100-mg bedaquiline tablets suspended in water versus
when administered in healthy adult volunteers to inform its use in children [58]. This does not
eliminate the need for making pediatric formulations available but does improve access to
much-needed medications during the timeframe following trial completion and drug registra-
tion until routine medication availability.
HIV-infected persons
Overview of TB in HIV-infected persons. Worldwide, an estimated 1,040,000 TB cases
and 300,000 TB deaths occurred among HIV-infected persons in 2017–86% of reported HIV-
associated TB deaths occurred in sub-Saharan Africa [1]. TB is 20–30 times more likely in the
context of HIV and remains the leading cause of death in this population. Adults and children
with advanced HIV disease (low CD4 count) are especially vulnerable. This subgroup has a
particularly high mortality rate [59] and is more likely to have disseminated TB disease and
more rapid disease progression. Despite this, a 2011 review revealed that many TB trials
exclude HIV-infected persons with CD4 counts < 200–350 cells/mm3 [60]; our review of
recent [61–64], currently enrolling, and registered (clinicaltrials.gov) randomized TB trials
suggests recent expansion of inclusion criteria, but HIV-infected persons with very low CD4
counts (<50–100 cells/mm3) remain frequently excluded (Table 4). Overall, clinical manage-
ment of dual TB–HIV disease is complex [12,65]. As in children, smear-negative TB disease is
common in the context of HIV, which poses challenges for TB diagnosis and treatment moni-
toring. In addition, polypharmacy arising from treatment of HIV, TB, and new/existing
comorbidities may increase adverse events and impact adherence and tolerability. Drug
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metabolism, absorption, and toxicity profiles may be altered in HIV, making longer courses of
treatment and side effects, such as neuropathy, liver injury, and rash, more likely [66,67].
Immune reconstitution inflammatory syndrome (IRIS)/paradoxical worsening, specific cyto-
chrome interactions, poor nutritional status, and chronic inflammation further impact HIV-
infected populations. As in children and pregnant women, physiologically based PK modeling
can help inform TB drug dosing in the setting of HIV but cannot replace data generated from
trials. In recent years, high-quality evidence has dramatically evolved the use and timing of TB
treatment in relation to ART [68]—persons with advanced HIV who are diagnosed with TB
are currently recommended to start ART within 2 weeks [69,70]. However, potential DDIs
remain a major concern for TB treatment in HIV-infected persons, particularly between anti-
retrovirals, such as protease inhibitors and integrase inhibitors, and rifamycins, key TB steriliz-
ing agents [12,65]. DDIs and adverse effects cannot always be readily identified from
observations in HIV-uninfected populations. A healthy-volunteer study assessing a TB-pre-
ventive regimen (rifapentine and isoniazid) and interaction with dolutegravir (HIV antiretro-
viral) found significant toxicity and was terminated early, yet these effects were not observed
in a larger study of HIV-infected persons [71,72]. It is important that TB trials assess the full
spectrum of HIV/TB and be sufficiently powered to evaluate the impact of HIV [41,60].
Trial design considerations and recommendations for TB disease and preventive thera-
pies in HIV-infected persons. Inclusion of HIV–TB-coinfected populations in TB clinical
trials poses a number of challenges. To enhance their enrollment, TB trials should be con-
ducted, at least in part, in geographic locations where HIV and TB epidemics coincide and
interact. Partnering with public-funded trials networks specializing in recruitment of HIV-
infected persons can facilitate this. For example, the US CDC Tuberculosis Trials Consortium
(TBTC)/AIDS Clinical Trials Group (ACTG) partnership has enhanced enrollment of HIV-
infected people in the Phase III randomized trial of rifapentine-containing shortened treat-
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eligibility also limits enrollment of HIV–TB-coinfected persons. Sensitivity of sputum smear
and culture are limited by low bacillary load of TB in the context of HIV [73]. As in young chil-
dren, less stringent measures, such as clinical TB diagnosis, could be incorporated. To ensure
balanced treatment assignments among various trial subgroups, randomization could be strat-
ified by HIV status (i.e., HIV-infected versus -uninfected) or by specific eligibility criteria (i.e.,
culture-confirmed versus nonconfirmed). Incorporating clinical TB diagnosis as a secondary
outcome measure (ideally reviewed by an expert committee blinded to treatment assignment)
may also be important for interpreting results in the overall trial population and in key sub-
groups. Outcome rates could also be assessed by HIV infection/HIV disease status and/or
ART use, as treatment outcomes in HIV–TB-coinfected patients may be highly dependent on
the specifics of ART management. Consistent with HIV and TB treatment guidelines, ART
should be required or expected to be initiated within 4–8 weeks of initiating TB treatment. It is
important to understand whether mortality or other poor outcomes in HIV–TB-coinfected
patients is related to HIV or TB. Thus, data analysis should be stratified by HIV infection/HIV
disease status (i.e., HIV-uninfected, HIV-infected with high CD4 count, and HIV-infected
with low CD4 count) to reduce concerns about any potential imbalances in subgroup numbers
between randomized arms.
Carefully designed DDI studies are a major element of clinical research of TB therapeutics
for treatment and prevention of TB in HIV-infected people, including HIV-infected adults
and children [74]. DDIs may be bidirectional, and the potential impact of host genetics is diffi-
cult to predict from small PK studies alone. To facilitate enrollment of HIV-infected individu-
als, DDI studies should be conducted early in drug development and/or nested in major trials
[41]. The Phase III randomized ACTG 5279 trial, “Short-Course Rifapentine/Isoniazid for
Treatment of Latent TB in HIV-Infected Individuals” (NCT01404312)[51], is an example of a
nested DDI study: the first 90 participants that were on efavirenz-based ART and randomized
to the rifapentine arm entered into a semi-intensive PK study [75] and were evaluated for PK/
PD and potential HIV virologic failure to confirm that efavirenz PK and ART outcomes
remained adequate. As in this example, the risk to a TB trial may be lower if PK of an HIV
drug is the concern, particularly for shorter periods of TB drug use. If the potential DDI
involves one of the TB drugs and may affect the randomized comparison, then an alternative
trial design might be used: HIV-infected individuals could be excluded from randomization to
the TB intervention but entered into a parallel PK cohort to evaluate the DDI. Once the poten-
tial DDI has been resolved, including by testing different drug dosing, randomization of HIV-
infected individuals might proceed expeditiously. Alternatively, an observational study could
be conducted whereby HIV-infected people who are on a targeted HIV drug and start a TB
drug of interest would undergo PK/PD evaluations. IMPAACT P1026s (NCT00042289) uses
this design to evaluate routinely used dosing of ART and TB (DS and DR TB) drugs during
pregnancy in HIV-infected and uninfected women. The key is to have an ongoing, approved
protocol in place that allows for targeted drugs to be studied without needing to develop a new
study for each potential DDI. Irrespective of the design used, the respective advantages and
disadvantages of intensive versus sparse drug sampling should be considered to facilitate rapid
enrollment and availability of information about potential DDIs.
Conclusions
TB therapeutic trials that exclude key populations are often not followed by trials in those pop-
ulations. Pregnant and lactating women, children, and HIV-infected persons contribute a
large proportion of the global TB burden and require optimized TB treatment and access to
the latest therapeutic advances. Overall, adequate inclusion and appropriate study of these
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populations remain problematic, particularly for pregnant and lactating women; some ad-
vances are being made for children, yet pediatric TB trials lag far behind adult trials despite
the potential for better TB treatment outcomes among children, and further evaluation of
DDIs is needed in HIV–TB-coinfected populations to ensure that HIV-infected persons, par-
ticularly those with more advanced HIV disease, more fully benefit from therapeutic advances.
Importantly, despite the differences among these populations, several cross-cutting themes
exist and can serve as a way forward toward inclusion of key populations in TB clinical trials
(Box 2).
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Box 2. Summary of recommendations and cross-cutting issues
among key populations
1. Pregnant and lactating women, children, and HIV-infected persons have
increased susceptibility to TB and variable responses during TB treatment, which
cannot be predicted by modeling data alone. Inclusion into clinical trials—espe-
cially Phase IIb and beyond—is often the best way to generate population-specific
data, as postmarketing studies are not prioritized and cause delay in obtaining
needed information.
2. Ethics are not a reason to exclude people from clinical trials, but careful consider-
ation of design and involvement of content experts, regulatory agency inputs, and
community participation is critical to ensure appropriate trial design and imple-
mentation. Inclusion will continue to require careful risks and benefits assess-
ments, weighing direct benefits alongside potential risks of adverse effects from
interventions on a case-by-case basis. The uncertainty cost of uniform exclusion
results in lack of guidance to inform use of these important TB therapies.
3. Design of trials requires careful attention to how safety, risks, and benefits are
defined and measured. Novel approaches may be useful, such as desirability of
outcome ranking (DOOR)/response adjusted for duration of antibiotic risk
(RADAR), a methodology that integrates overall clinical outcome and patient-
level risks and benefits and was specifically developed for clinical trials comparing
strategies to optimize antibiotic use [76].
4. Rigorous qualitative research is useful to inform trial design and elicit patient,
caregiver, and family preferences regarding trial participation and regimens.
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